Taiwan-based Apex Medical Corporation has announced its foray into the Indian market, with big plans to invest about Rs 100 crore.
The company, which is mainly into manufacturing of respiratory therapy and supports surface products, will initially import its products and sell them in the country through local dealers, hospitals and tenders to the government.
Significantly, Daniel Lee, CEO, Apex Medical Corporation told mediapersons, "The Indian healthcare market is growing at 12-15 per cent, we expect Apex in India to grow at least by 5 times in the next five years.”
The three product verticals that company will focus are respiratory, support surface and autoclaves.
"We intend to offer best quality products at best and most affordable prices to medical personnel, care givers and consumers in the sub continent," informed Lee.
Commenting on the future plans to manufacture the products in India, Lee said, "In the initial phase, we will only be marketing the products in India."
Meanwhile, Puneet Sahai, President, Apex Medical India said, "The Company will adopt three routes to sell products in India, through local dealers, through hospitals and through tenders to government.”
Established in 1990, Apex Medical Corporation has created over 100 product trademarks and patents worldwide. Currently, the company markets its products in 60 countries across the globe.
